JPRN-UMIN000053277已完成Unknown
Multiple oral antibiotics therapy for induction and maintenance of ulcerative colitis - Multiple oral antibiotics therapy for ulcerative colitis
Juntendo University Graduate School of Medicine0 个研究点目标入组 320 人开始时间: 2024年1月5日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 320
研究概览
简要总结
The compliance rate was 95.7%. The response rate and remission rate were 75.2% and 30.9% at completion, 62.7% and 29.6% at 3 months, 48.2% and 27.7% at 6 months, 37.9% and 24.4% at 9 months, 35.4% and 24.4% at 12 months, respectively. The most frequent adverse events were diarrhea and fever. No life-threatening adverse events were observed during the trial.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15years-old 至 ot applicable(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •Exclusion criteria were penicillin allergy, administration of antibiotics agents within 2 weeks of study entry, ongoing biologic therapy, pregnancy, cancer and other serious comorbid illness. Patients who had stool pathogens including Clostridium difficile, Salmonellae, pathogenic Escherichia coli were also excluded.
研究者
相似试验
已完成
不适用
ADAPT Studychronic constipationJPRN-jRCTs031180069Ohbayashi Hiroyuki150
已完成
不适用
A prospective multicenter study for characterization of renal function G1b CHC patients with CKD-3 treated with elbasvir plus grazoprevirJPRN-UMIN000026542Kyushu University80
已完成
2 期
KRP-AM1977X Phase II Clinical StudyMild to moderate community acquired pneumonia (including Mycoplasma pneumonia, Chlamydia Pneumonia, or Legionella pneumonia)JPRN-jRCT2080222226Kyorin Pharmaceutical Co.,LTD129
已完成
不适用
Clinical factor for clinicians to choose treatments to refractory ulcerative colitis patients, and the validity of the treatment.JPRN-UMIN000025277agasaki university graduate school of Biomedecal Science Department of Gastroenterology and hepatology150
已完成
2 期
Randomized pilot study of optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with mFOLFOX6: HGCSG0703colorectal cancerJPRN-UMIN000017576Hokkaido Gastrointestinal Cancer Study Group (HGCSG)40
